Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.

Li Z, Zhang Y, Quan X, Yang Z, Zeng X, Ji L, Sun F, Zhan S.

PLoS One. 2016 May 9;11(5):e0154206. doi: 10.1371/journal.pone.0154206. eCollection 2016.

2.

A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.

Hoelmkjaer KM, Wewer Albrechtsen NJ, Holst JJ, Cronin AM, Nielsen DH, Mandrup-Poulsen T, Bjornvad CR.

PLoS One. 2016 May 2;11(5):e0154727. doi: 10.1371/journal.pone.0154727. eCollection 2016.

3.

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists.

Kang YM, Jung CH.

Endocrinol Metab (Seoul). 2016 Jun;31(2):258-74. doi: 10.3803/EnM.2016.31.2.258. Epub 2016 Apr 25. Review.

4.

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future.

Kalra S, Baruah MP, Sahay RK, Unnikrishnan AG, Uppal S, Adetunji O.

Indian J Endocrinol Metab. 2016 Mar-Apr;20(2):254-67. doi: 10.4103/2230-8210.176351. Review.

5.

Pancreatic regulation of glucose homeostasis.

Röder PV, Wu B, Liu Y, Han W.

Exp Mol Med. 2016 Mar 11;48:e219. doi: 10.1038/emm.2016.6. Review.

6.

The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.

de Wit HM, Te Groen M, Rovers MM, Tack CJ.

Br J Clin Pharmacol. 2016 Jul;82(1):301-14. doi: 10.1111/bcp.12925. Epub 2016 Apr 22. Review.

PMID:
26935973
7.

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Nauck MA, Stewart MW, Perkins C, Jones-Leone A, Yang F, Perry C, Reinhardt RR, Rendell M.

Diabetologia. 2016 Feb;59(2):266-74. doi: 10.1007/s00125-015-3795-1. Epub 2015 Nov 17.

8.

Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.

Shomali M.

Clin Diabetes. 2014 Jan;32(1):32-43. doi: 10.2337/diaclin.32.1.32. No abstract available.

9.

Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance.

Tella SH, Rendell MS.

Ther Adv Endocrinol Metab. 2015 Jun;6(3):109-34. doi: 10.1177/2042018815580257. Review.

10.

GLP-1 based therapeutics: simultaneously combating T2DM and obesity.

Heppner KM, Perez-Tilve D.

Front Neurosci. 2015 Mar 20;9:92. doi: 10.3389/fnins.2015.00092. eCollection 2015. Review.

11.

Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus.

Harris KB, McCarty DJ.

Ther Adv Endocrinol Metab. 2015 Feb;6(1):3-18. doi: 10.1177/2042018814558242. Review.

12.

Cardiovascular safety profile of currently available diabetic drugs.

Azimova K, San Juan Z, Mukherjee D.

Ochsner J. 2014 Winter;14(4):616-32. Review.

13.

Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis.

Sun F, Chai S, Yu K, Quan X, Yang Z, Wu S, Zhang Y, Ji L, Wang J, Shi L.

Diabetes Technol Ther. 2015 Jan;17(1):35-42. doi: 10.1089/dia.2014.0188. Review.

14.

Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.

Tate M, Chong A, Robinson E, Green BD, Grieve DJ.

Br J Pharmacol. 2015 Feb;172(3):721-36. doi: 10.1111/bph.12943. Epub 2014 Dec 1. Review.

15.

Treating the elderly diabetic patient: special considerations.

Kezerle L, Shalev L, Barski L.

Diabetes Metab Syndr Obes. 2014 Aug 28;7:391-400. doi: 10.2147/DMSO.S48898. eCollection 2014. Review.

16.

Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.

Stranges P, Khanderia U.

Ther Adv Drug Saf. 2012 Aug;3(4):185-201. doi: 10.1177/2042098612454290. Review.

17.

Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.

Blaslov K, Bulum T, Zibar K, Duvnjak L.

World J Gastroenterol. 2014 Jun 21;20(23):7356-65. doi: 10.3748/wjg.v20.i23.7356. Review.

18.

Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism.

Krasner NM, Ido Y, Ruderman NB, Cacicedo JM.

PLoS One. 2014 May 16;9(5):e97554. doi: 10.1371/journal.pone.0097554. eCollection 2014.

19.

Effects of GLP-1 on appetite and weight.

Shah M, Vella A.

Rev Endocr Metab Disord. 2014 Sep;15(3):181-7. doi: 10.1007/s11154-014-9289-5. Review.

20.

Efficacy of liraglutide in a real-life cohort.

Heymann A, Maor Y, Goldstein I, Todorova L, Schertz-Sternberg P, Karasik A.

Diabetes Ther. 2014 Jun;5(1):193-206. doi: 10.1007/s13300-014-0062-2. Epub 2014 Mar 25.

Items per page

Supplemental Content

Write to the Help Desk